Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies.

Cancer Clinical Trial

— MARTINI  

Official title:

Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04853420
• Other study ID #: 0792
• Status: Active, not recruiting
• Start date: February 16, 2021
• Est. completion date: April 30, 2026

Study information

• Verified date: March 2023
• Source: University of Leicester
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The NHS' Genomic Medicine Service offers whole genome sequencing as part of the drive to improve cancer outcomes. It is recognised that actionable mutations (current and emerging), will ultimately improve outcomes across multiple disease sites by identifying which treatments may benefit individual patients the most, and by providing earlier and more accurate diagnoses. However, testing in the cancer setting is currently limited to haematological malignancies and sarcoma. The majority of patients with solid tumours do not yet have access to this platform and the benefits that it may bring. Therefore, expanding genomic testing capacity within a research setting has potential to benefit those patients that would otherwise not be able to access testing. In this study we will be using tissue derived from patients undergoing surgery for cancer to validate an in-house genomic testing platform against Roche's Foundation Medicine genomic profile service, which is an FDA- approved commercial platform.

In addition, two blood samples will be taken in order that we can test whether markers present in the tissue may also be seen in blood. We hope that this will help us monitor minimal residual disease in patients, allowing earlier detection of relapse/recurrence than radiology currently allows.

Patients may also agree to donate optional excess fresh tissue from their surgery. This will be integrated with other laboratory platforms which may offer information on prospective drug response based on genotypic profiles (e.g., patient-derived explants).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in the study.

• Male or Female, aged 18 years or above.

• Diagnosed with solid tumour that requires surgical resection, and has a high propensity of relapse.

• Fit for planned surgical procedure.

• Able (in the Investigators opinion) and willing to comply with all study requirements.

• Willing to allow his or her General Practitioner, Consultant, and Clinical Geneticist, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

• Female participants who are pregnant, lactating or planning pregnancy during the course of the study.

• Not fit for surgery.

• Not willing to donate blood and tissue samples.

• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

• Participants who have participated in another research study involving an investigational product in the past 12 weeks.

Related Conditions & MeSH terms

• Cancer
• Neoplasm, Residual

Locations

Country	Name	City	State
United Kingdom	University Hospitals of Leicester	Leicester

Sponsors (1)

Lead Sponsor	Collaborator
University of Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cross-validate the in-house genetic testing platform against the FDA approved Foundation Medicine	To cross-validate the Thermofisher Oncomine tissue and cfTNA assays (in house) against the FDA approved Foundation Medicine platform by comparison of the spectrum and variant frequency of cancer-specific alterations detected in matched tissue and blood.	12-24 months
Secondary	Assess Utility in detecting minimal residual disease	To compare ctDNA mutations and variant frequency in blood samples pre- and post-surgery to assess utility in detection of minimal residual disease	12-24 months
Secondary	Data integration	Ability to integrate data from clinical risk factors, and up-front genotyping.	12-24 months
Secondary	Feasibility of testing platform in clinical setting	Feasibility of returning laboratory analysis in a clinically meaningful timeframe.	12-24 months